CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30
Cencora, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$340.00−0.92 (-0.27%)
Close on Oct 19, 2026
- Market cap
- $65.94B
- P/E (TTM)
- 25.2
- Dividend yield
- 0.65%
Cencora, Inc. revenue by segment
By business segment
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | $74.86B | $68.77B | $76.21B | $80.26B | $71.34B | $66.82B | $72.56B | $71.67B | $67.19B | $61.29B | $65.18B | $61.93B | 88.3% | +4.9% |
| International Healthcare Solutions | $7.68B | $7.57B | $7.62B | $9.46B | $7.25B | $6.70B | $6.96B | $7.38B | $7.05B | $7.12B | $7.07B | $6.99B | 9.1% | +5.9% |
| Operating income | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Healthcare Solutions | $966.18M | $998.30M | $831.33M | $1.11B | $833.65M | $944.97M | $686.93M | $697.38M | $698.31M | $841.06M | $698.12M | $632.83M | +15.9% |
| International Healthcare Solutions | $165.85M | $175.80M | $142.16M | $191.22M | $137.28M | $154.60M | $165.18M | $153.67M | $179.39M | $192.72M | $187.60M | $168.16M | +20.8% |
By product or service
By region
From the segment and revenue-disaggregation notes of Cencora's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.